Verition Fund Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Verition Fund Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$475K	Buy	+3,000	New	+$406K	﹤0.01%	1654
2021 Q3	–	Sell	-37,800	Closed	-$5.12M	–	2355
2021 Q2	$5.12M	Buy	+37,800	New	+$4.97M	0.05%	244

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Verition Fund Management's XBI Position: Q2 2026 in Review

Verition Fund Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.19% in Q2 2026, selling an estimated $11.2K and leaving 44,693 shares worth $7.07M. The position accounts for 0.04% of the portfolio, ranked #493.

Verition Fund Management first reported a position in XBI in Q2 2013 and has held it in 23 quarters since. The position peaked at $11.5M in Q2 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Verition Fund Management held 44,693 shares of State Street SPDR S&P Biotech ETF worth $7.07M as of Q2 2026.
Verition Fund Management sold 83 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $11.2K.
State Street SPDR S&P Biotech ETF made up 0.04% of Verition Fund Management's portfolio in Q2 2026, its #493 holding.
Verition Fund Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 23 quarters since.
Verition Fund Management's State Street SPDR S&P Biotech ETF position peaked at $11.5M in Q2 2025.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.